Conference - The future of ARVs in Africa

 

We are delighted to announce the 3rd Southern African HIV Clinicians Society (SAHCS) long-acting treatment and prevention conference: ‘The future of antiretrovirals in Africa: Long-acting agents and beyond’. 

The conference is set to take place on Tuesday, 15 September 2026 at the Maslow Hotel, corner of Rivonia Road and Grayston Drive, Sandton, Johannesburg, South Africa.


This conference has grown from strength to strength, highlighting the need for a meeting for healthcare professionals focussed on long-acting HIV treatment and prevention, reviewing the latest research from studies, and having stimulating discussions around guidelines and readiness for implementation.  

The full-day CPD-accredited conference will provide healthcare professionals with up-to-date clinical knowledge and clinical skills development around patient treatment, care and support. 

Registration will open soon. 

If you have any questions, please do not hesitate to contact the secretariat, Janice Candlish, at janice@sahivcs.org or telephone +27(0)11 728 7365.

 


Previous conference information:


2nd Southern African HIV Clinicians Society (SAHCS) long-acting treatment and prevention conference: ‘The future of antiretrovirals in Africa: Long-acting agents and beyond’
Tuesday, 29 October 2024 | Johannesburg, South Africa

Conference programme - Click here
Conference presentations:
Long-acting agents - where do these products fit in the African context? | Dr Catherine Orrell
Lenacapavir, a novel capsid inhibitor for HIV treatment and prevention | Prof Francois Venter
From trial to implementation – can IMPALA help us jump across the gap? | Dr Nigel Garrett
What are the treatment options for patients with multidrug-resistant HIV-1 infection? | Dr Mohammed Rassool
What is the role of lenacapavir in future first-line HIV treatment? | Prof Francois Venter
How long-acting injectable ART could help adolescent and young adults | Dr Lauren Jennings
Pre-exposure prophylaxis in adolescent girls and young women at risk of HIV infection | Dr Nkosiphile Ndlovu
Uptake and retention of adolescents and young adults in differentiated HIV prevention | Prof Maryam Shahmanesh
LA medications: Where do they fit in for niche populations in an African context? | Prof Lee Fairlie
Long-acting PrEP in Pregnancy and Breastfeeding | Dr Dvora Joseph Davey
Advancements in Neonatal HIV Therapy | Dr Adrie Bekker
Progress towards bringing Long-acting ART to children and adolescents | Mo Archary
Assessing the demographic, risk profile, and clinical characteristics of early PrEP adopters | Dr Pippa Macdonald
PrEP LA implementation in Botswana | Dr Ava Avalos
 


1st SAHCS long-acting HIV treatment and prevention conference
20 September 2022 | Johannesburg, South Africa

Conference programme – download here
Conference presentations: